23ANDME HOLDING CO -CLASS A (ME)
US90138Q1085 - Common Stock
ME gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 117 industry peers in the Health Care Providers & Services industry. ME scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. ME does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
In the past year ME has reported negative net income.
ME had a negative operating cash flow in the past year.
ME had negative earnings in each of the past 5 years.
In the past 5 years ME always reported negative operating cash flow.
1.2 Ratios
With a Return On Assets value of -85.82%, ME is not doing good in the industry: 91.38% of the companies in the same industry are doing better.
The Return On Equity of ME (-138.39%) is worse than 79.31% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -85.82% | ||
| ROE | -138.39% | ||
| ROIC | N/A |
ROA(3y)-30.85%
ROA(5y)N/A
ROE(3y)-47.79%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ME has a better Gross Margin (45.29%) than 75.86% of its industry peers.
ME's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for ME so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 45.29% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.05%
GM growth 5YN/A
2. Health
2.1 Basic Checks
ME does not have a ROIC to compare to the WACC, probably because it is not profitable.
ME has more shares outstanding than it did 1 year ago.
ME has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
ME has an Altman-Z score of -5.00. This is a bad value and indicates that ME is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -5.00, ME is not doing good in the industry: 84.48% of the companies in the same industry are doing better.
ME has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -5 |
ROIC/WACCN/A
WACC9.29%
2.3 Liquidity
A Current Ratio of 2.15 indicates that ME has no problem at all paying its short term obligations.
With a decent Current ratio value of 2.15, ME is doing good in the industry, outperforming 79.31% of the companies in the same industry.
A Quick Ratio of 2.04 indicates that ME has no problem at all paying its short term obligations.
The Quick ratio of ME (2.04) is better than 79.31% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.15 | ||
| Quick Ratio | 2.04 |
3. Growth
3.1 Past
ME shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -38.00%.
Looking at the last year, ME shows a very negative growth in Revenue. The Revenue has decreased by -19.39% in the last year.
Measured over the past years, ME shows a decrease in Revenue. The Revenue has been decreasing by -0.66% on average per year.
EPS 1Y (TTM)-38%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-700%
Revenue 1Y (TTM)-19.39%
Revenue growth 3Y-0.66%
Revenue growth 5YN/A
Revenue growth Q2Q-33.11%
3.2 Future
Based on estimates for the next years, ME will show a very negative growth in Earnings Per Share. The EPS will decrease by -10.57% on average per year.
ME is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 11.38% yearly.
EPS Next Y-122.16%
EPS Next 2Y-11.4%
EPS Next 3Y-3.12%
EPS Next 5Y-10.57%
Revenue Next Year-27.26%
Revenue Next 2Y-5.76%
Revenue Next 3Y0.58%
Revenue Next 5Y11.38%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
ME reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ME is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
ME's earnings are expected to decrease with -3.12% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-11.4%
EPS Next 3Y-3.12%
5. Dividend
5.1 Amount
ME does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
23ANDME HOLDING CO -CLASS A
NASDAQ:ME (4/25/2024, 6:25:13 PM)
After market: 0.469 +0.01 (+2.18%)0.459
-0.01 (-1.73%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap221.66M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -85.82% | ||
| ROE | -138.39% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 45.29% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.41
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 2.15 | ||
| Quick Ratio | 2.04 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-38%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-122.16%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-19.39%
Revenue growth 3Y-0.66%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y